ABEO
Abeona Therapeutics Inc.
NASDAQ · USHealthcareBiotechnology
$6.48-7.43%
Price as of Jul 20, 2026
ABEO financials
Abeona Therapeutics Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $5.8M | $0.00 | $3.5M | $1.4M |
| Cost of revenue | $1.5M | $2.9M | $1.6M | $450.0K |
| Gross profit | $4.3M | -$2.9M | $1.9M | $964.0K |
| Operating expenses | $93.7M | $61.3M | $49.0M | $51.9M |
| Operating income | -$89.4M | -$64.2M | -$47.1M | -$50.9M |
| Net income | $71.2M | -$63.7M | -$54.2M | -$39.7M |
| EBITDA | $78.6M | -$56.6M | -$50.6M | -$34.4M |
| Basic EPS | $1.34 | $-1.55 | $-2.53 | $-5.53 |
| Diluted EPS | $1.01 | $-1.55 | $-2.53 | $-5.53 |
| Balance sheet | ||||
| Cash & equivalents | $78.4M | $23.4M | $14.5M | $14.2M |
| Total assets | $219.6M | $108.9M | $64.0M | $64.2M |
| Total liabilities | $60.4M | $64.9M | $49.2M | $37.5M |
| Stockholders’ equity | $159.2M | $44.0M | $14.8M | $26.8M |
| Total debt | $25.0M | $23.0M | $5.4M | $7.6M |
| Net debt | -$53.5M | -$309.0K | -$9.1M | -$6.6M |
| Cash flow | ||||
| Operating cash flow | -$76.3M | -$56.0M | -$37.0M | -$43.5M |
| Capital expenditure | -$8.0M | -$2.4M | -$331.0K | -$130.0K |
| Free cash flow | -$84.3M | -$58.5M | -$37.3M | -$43.6M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |